Skip to main navigation Skip to main content

The University of Southampton

×

Dr Juliet Gray MA, MB BS, FRCPCH, PhD

Associate Professor and Consultant in Paediatric Oncology

Related links

Dr Juliet Gray is an Associate Professor in Paediatric Oncology within Medicine at the University of Southampton

Dr Gray graduated from Cambridge University and the Royal Free Hospital School of Medicine. She completed her clinical training in Paediatric Oncology at Southampton, Great Ormond Street and the Royal Marsden hospitals. During her training she was awarded a Cancer Research UK Clinical Research Fellowship, which allowed her to complete a PhD in cancer immunotherapy within the Cancer Sciences Unit, University of Southampton. In 2006, she was appointed at a NIHR Clinical Lecturer in Paediatric Oncology, and as a Senior Lecturer in Paediatric Oncology in 2010. She is an honorary Consultant in Paediatric Oncology at University Hospital Southampton NHS Foundation Trust (UHSFT), where she leads the clinical Paediatric Oncology and Haematology department.

Qualifications

MA, Medical Sciences Tripos, Cambridge University (1991)
MB BS, University of London (1994)
PhD, Cancer Immunotherapy, University of Southampton (2007)

Appointments held

Great Ormond Street Hospital, London (SHO in Paediatric Oncology, 1998)

Royal Marsden Hospital (Paediatric Oncology Clinical Research Fellow, 1999)

Portsmouth Hospitals (Paediatric Registrar, 1999-2001)

Southampton General Hospital (Paediatric Oncology registrar, 2001-2002)

University of Southampton, Cancer Sciences Division (Cancer Research UK Clinical Research Fellow, 2002-2006)

Royal Marsden Hospital (Paediatric Bone Marrow Transplant Fellow, 2007-2008)

Clinical Lecturer in Paediatric Oncology, (2006-2010)

University of Southampton (Associate Professor and Consultant in Paediatric Oncology, 2010 - present)

Research

Responsibilities

Publications

Teaching

Contact

Research interests

Dr Gray’s main research interest is in the development of new immunotherapies to treat neuroblastoma, one of the commonest childhood cancers. Neuroblastoma is a tumour of neuroectodermal origin that usually develops in very young children. Unfortunately, in the majority of children the disease is metastatic by the time of diagnosis, and survival rates for these children remain poor despite intensive conventional therapies. Toxicity from these therapies is significant and new therapies are needed to improve outcome. Dr. Gray’s translational research group focuses on novel antibody immunotherapies for neuroblastoma, including preclinical evaluation of combinational therapies as well as early phase clinical trials. Her specific research interests include anti-GD2 and immunomodulatory antibodies, such as those targeting PD-1. Her pre-clinical work includes understanding and optimising mechanisms of action of such antibodies and investigating how they can best be combined with existing cancer therapies. She also leads a number of early phase immunotherapy trials, including the first ever transatlantic neuroblastoma trial, which is investigating combining 131-I mIBG radionucleotide therapy with anti-GD2 and anti-PD-1 monoclonal antibodies.

Funding: Cancer Research UK, Solving Kids Cancer, Wilberry’s Research

Is a member of the team for the Centre for Cancer Immunology, Cancer Sciences

Department(s)

Cancer Sciences

Affiliate Department(s)

Cancer Sciences Research group

Member of NCRI Children’s Cancer and Leukaemia Clinical Study Group
Chair of NCRI CCL CSG Neuroblastoma subgroup
Member of European Neuroblastoma Research Network (SIOPEN) Executive Committee
Member of UK Children’s Cancer and Leukaemia Group (CCLG) New Agents Group.
Member of Cancer Research UK Protocol Safety Review Board
Southampton Paediatric ECMC lead, member of national ECMC steering group, and co-lead for Immunotherapy theme
CCLG Clinical Trial Lead for the Southampton Paediatric Oncology Centre
Chair of the Southampton Paediatric Chemotherapy Group and a member of UHSFT Drugs Committee
Member of Scientific Advisory Board, Solving Kids Cancer
Chair Wessex Paediatric Oncology and Haematology Network
Member of UK National Neuroblastoma Advisory Panel
Member of Scientific Advisory Board, Neuroblastoma Australia

Sort via:TypeorYear

Articles

Book

Gray, J. C., & Marabelle, A. (2018). Immunotherapy for Pediatric Malignancies. Springer. https://doi.org/10.1007/978-3-319-43486-5

Book Chapter

Gray, J. (2016). High-count T cell acute lymphoblastic leukaemia with treatment stratification based on minimal residual disease response. In E. Copson, P. Hall, R. Board, G. Cook, & P. Selby (Eds.), Problem Solving Through Precision Oncology: a Case Study Based Reference and Learning Resource EBN Health.

Patent

Frendeus, B., Martensson, L., Semmrich, M., Teige, I., Beers, S., Al-Shamkhani, A., Gray, J., & Glennie, M. (2019). Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody. (Patent No. WO2019020774-A2).

Reviews

Smith, H. L., Beers, S., Gray, J., & Kanczler, J. (2020). The role of pre-clinical 3-dimensional models of osteosarcoma. International Journal of Molecular Sciences, 21(15), 1-12. [5499]. https://doi.org/10.3390/ijms21155499
Moreno-Vicente, J., Beers, S. A., & Gray, J. C. (2019). PD-1/PD-L1 blockade in paediatric cancers: What does the future hold? Cancer Letters, 457, 74-85. https://doi.org/10.1016/j.canlet.2019.04.025

External examiner University of Nottingham MSc Cancer Immunology and Biotechnology
PhD supervisor and examiner
BMedSci and MMedSci project supervisor

Dr Juliet Gray
Phone: (023) 8120 6639 Fax: (023) 8120 4061 Email: jcgray@soton.ac.uk

Room Number: SGH/CCI/MP127

Share this profile Share this on Facebook Share this on Twitter Share this on Weibo

Privacy Settings